At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 734 enrolled
Drug / intervention
Brolucizumab 6 mg +1 morebiological
Likely dose
Brolucizumab 6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 64-week, Two-arm, Randomized, Double-masked, Multicenter, Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen in Patients With Neovascular Agerelated Macular Degeneration (TALON)
In Brief
A Phase 3 clinical trial evaluating Brolucizumab 6 mg and Aflibercept 2 mg for Age-related Macular Degeneration. Completed, enrolled 734 participants across 118 sites in 20 countries.
Detailed Summary
This was a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with neovascular age related macular degeneration (nAMD) who have not previously received anti- vascular endothelial growth factor (VEGF) treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-related Macular Degeneration
CountriesArgentina, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Israel, Italy, Malaysia, Netherlands, Portugal, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedJul 2019
Enrollment StartSep 2019
Primary CompletionSep 2022
TodayJul 2026
First PostedJul 2, 2019
Enrollment StartSep 25, 2019
Primary CompletionSep 9, 2022
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 7 years ago
Interventions
Brolucizumab 6 mgbiological
Intra-vitreal injection
Aflibercept 2 mgbiological
Intra-vitreal injection